CNI MONITOR.
Developed by doctors for doctors.

The new tool for drug efficacy. VISIT US on Chronix Booth #5147

Chronix Biomedical has published recently its results of a blinded prospective clinical trial validating the use of the CNI MONITOR blood test to predict treatment outcome of patients undergoing therapy. Meet the experts involved with the study.

„The key finding is the ability of the test to make an early prediction of response and disease control, just three to four weeks after initiation of immunotherapy. The flexibility to switch treatments early on based on an accurate prediction has great potential to improve the treatment of many cancers.”

Glen J. Weiss, MD, MBA and principal investigator of the Clinical Cancer Research March publication.

logo AACR

Weiss GJ, et al. Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy

Take part in Chronix Biomedical clinical study program. Join us in:
#TheTurningPointInCancerFight